peplexicon
Choose your depth

Context, anatomy, and key evidence

← Peptide library

zonulin antagonist

Larazotide

Published evidence · coverage incomplete
Anatomical contextAnatomy connections are not mapped yet.

No body region is highlighted until this profile has a supported anatomical connection. This does not mean the peptide has no biological effects.

Read published mechanism findings ↓

At a glance

What is it—and why does it matter?

The entry lists alternative names (synonyms) for Larazotide: AT-2347, Larazotida, and Larazotide.

Sources for this introduction: [1]

This published profile is a reference in progress. Findings retain their source context; missing topics are marked below.

What is it?

A molecule, not a product name.

Identity

Larazotide acetate is identified as a zonulin inhibitor (i.e., an agent that inhibits zonulin-related modulation of intestinal barrier function).

Sources[5]pubmedPotassium-Competitive Acid Blocker Increases Ileal Permeability and Exacerbates Ileal Inflammation under Stress Conditions in a Mouse Model of Eosinophilic Enteritis.Larazotide acetate, a zonulin inhibitor,
Source records
1
Independent studies
1

Evidence boundary: Applies only to the source-defined population, formulation, dose, and assessment period.

Exact passages, locators, and provenance
  1. supports · Source-backed record
    “Larazotide acetate, a zonulin inhibitor,”

    Potassium-Competitive Acid Blocker Increases Ileal Permeability and Exacerbates Ileal Inflammation under Stress Conditions in a Mouse Model of Eosinophilic Enteritis. · RESULTS

    pubmed:42008374:6b75c22c9858:6b75c22c9858

Identity

HSMP-LA is described as a dual-crosslinked hyaluronic-acid-based hydrogel formulation that contains (co-loads) the antimicrobial polymer ε-polylysine and the peptide drug larazotide acetate.

Sources[3]pubmedAntibacterial hyaluronic acid hydrogel with sustained release of larazotide as effective colitis treatment.Herein, inspired by natural gut mucus, a dual-crosslinked hydrogel (HSMP-LA) composed of thiol/maleimide-modified hyaluronic acid together with co-loading of antimicrobial ε-polylysine (ε-PL) and larazotide acetate (LA) had been developed as an injectable artificial gut mucus to simultaneously restore barrier integrity and modulate gut microbiota.
Source records
1
Independent studies
1

Evidence boundary: Applies only to the source-defined population, formulation, dose, and assessment period.

Exact passages, locators, and provenance
  1. supports · Source-backed record
    “Herein, inspired by natural gut mucus, a dual-crosslinked hydrogel (HSMP-LA) composed of thiol/maleimide-modified hyaluronic acid together with co-loading of antimicrobial ε-polylysine (ε-PL) and larazotide acetate (LA) had been developed as an injectable artificial gut mucus to simultaneously restore barrier integrity and modulate gut microbiota.”

    Antibacterial hyaluronic acid hydrogel with sustained release of larazotide as effective colitis treatment. · Abstract

    pubmed:40915363:313948de4913:313948de4913

Identity

The entry lists alternative names (synonyms) for Larazotide: AT-2347, Larazotida, and Larazotide.

Sources[1]chembl-moleculeLARAZOTIDEMolecular weight: 725.85[1]chembl-moleculeLARAZOTIDEMolecular formula: C32H55N9O10[1]chembl-moleculeLARAZOTIDEPreferred name: LARAZOTIDE[1]chembl-moleculeLARAZOTIDEMolecule type: Protein[1]chembl-moleculeLARAZOTIDEAT-2347; Larazotida; Larazotide[2]iuphar-commentsIUPHAR ligand commentaryIts sequence is derived from the zonula occludens toxin that is secreted by Vibrio cholerae.
Source records
6
Independent studies
2

Evidence boundary: Applies only to the source-defined population, formulation, dose, and assessment period.

Exact passages, locators, and provenance
  1. supports · Source-backed record
    “Molecular weight: 725.85”

    LARAZOTIDE · Molecular properties

    chembl-molecule:chembl2105646:9116da5f17d1:9116da5f17d1
  2. supports · Source-backed record
    “Molecular formula: C32H55N9O10”

    LARAZOTIDE · Molecular properties

    chembl-molecule:chembl2105646:9116da5f17d1:9116da5f17d1
  3. supports · Source-backed record
    “Preferred name: LARAZOTIDE”

    LARAZOTIDE · Molecule identity

    chembl-molecule:chembl2105646:9116da5f17d1:9116da5f17d1
  4. supports · Source-backed record
    “Molecule type: Protein”

    LARAZOTIDE · Molecule identity

    chembl-molecule:chembl2105646:9116da5f17d1:9116da5f17d1
  5. supports · Source-backed record
    “AT-2347; Larazotida; Larazotide”

    LARAZOTIDE · Synonyms

    chembl-molecule:chembl2105646:9116da5f17d1:9116da5f17d1
  6. supports · Source-backed record
    “Its sequence is derived from the zonula occludens toxin that is secreted by Vibrio cholerae.”

    IUPHAR ligand commentary · General comments

    iuphar-comments:13724:a1ebfdd2eb89:a1ebfdd2eb89

Identity

Larazotide acetate (LA) is a synthetic peptide composed of eight amino acids (an octapeptide).

Sources[4]pubmedLarazotide Acetate Protects the Intestinal Mucosal Barrier from Anoxia/Reoxygenation Injury via Various Cellular Mechanisms.Larazotide acetate (LA) is a synthetic octapeptide
Source records
1
Independent studies
1

Evidence boundary: Applies only to the source-defined population, formulation, dose, and assessment period.

Exact passages, locators, and provenance
  1. supports · Source-backed record
    “Larazotide acetate (LA) is a synthetic octapeptide”

    Larazotide Acetate Protects the Intestinal Mucosal Barrier from Anoxia/Reoxygenation Injury via Various Cellular Mechanisms. · Abstract

    pubmed:41153766:510c563e45cf:510c563e45cf

How does it work?

Target, response, and disposition.

This profile does not yet contain a published summary for this topic. This is a coverage gap, not evidence that no research exists.

What has been studied?

What the evidence says.

This profile does not yet contain a published summary for this topic. This is a coverage gap, not evidence that no research exists.

Risks and interactions

Risks, organized for scanning.

This profile does not yet contain a published summary for this topic. This is a coverage gap, not evidence that no research exists.

Products and regulatory status

Same ingredient. Different records.

This profile does not yet contain a published summary for this topic. This is a coverage gap, not evidence that no research exists.

Administration context

The practical clinical context.

This profile does not yet contain a published summary for this topic. This is a coverage gap, not evidence that no research exists.

Research status + gaps

What still needs better answers?

  • No publishable claim yet for: administration, contraindication, effect, interaction, mechanism, regulatory, safety
  • 27 compiled claim(s) withheld by automated assurance: assurance_score_below_0.58 (19), assurance_score_below_0.72 (7), current_regulatory_source_required (6), extraction_ambiguity (22), high_risk_requires_regulatory_or_two_independent_sources (7), no_direct_support (25)

These are the limits of this profile, not an exhaustive list of scientific uncertainties.

References + discovery

Open the records yourself.

  1. LARAZOTIDE ↗

    chembl-molecule · published 2026-08-27 · retrieved 2026-08-27T19:16:08Z

  2. IUPHAR ligand commentary ↗

    iuphar-comments · published 2026-08-27 · retrieved 2026-08-27T11:48:55Z

  3. Antibacterial hyaluronic acid hydrogel with sustained release of larazotide as effective colitis treatment. ↗

    pubmed · published 2025-11-10 · retrieved 2026-08-27T11:48:55Z

  4. Larazotide Acetate Protects the Intestinal Mucosal Barrier from Anoxia/Reoxygenation Injury via Various Cellular Mechanisms. ↗

    pubmed · published 2025-10-12 · retrieved 2026-08-27T11:48:55Z

  5. Potassium-Competitive Acid Blocker Increases Ileal Permeability and Exacerbates Ileal Inflammation under Stress Conditions in a Mouse Model of Eosinophilic Enteritis. ↗

    pubmed · published 2026-04-20 · retrieved 2026-08-27T11:48:55Z

Publication history and provenance

Version 3 · Automated assessment · 2026-08-27T19:16:08Z

f25c235c99df565a045008d8515fcdf0dbf05dfd2476370655e457937c32867a